AGL at a glance
agilon health, inc. (AGL, SEC CIK 1831097) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as August 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), agilon health, inc. (AGL) reported revenue of $5.9 billion (down 2.1% from FY2024) and a net loss of $391.3 million.
- As of December 31, 2025, 25 institutional investment managers tracked by SignalX reported holding agilon health, inc. (AGL) shares worth $114.2 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $5.9B
- −2.1% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 25 funds
- $114.2M · +1 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly triggered liquidity risk: Third Amendment requires minimum Total Cash of $50.0 million daily and 100% cash collateralization of letters of credit
- Most materially updated debt risk: Term-loan maturity extended to February 18, 2028, while revolving commitments fell to $90.0 million
- Regulatory and compliance risk: CMS risk-adjustment settlements typically arrive 12 to 18 months later, creating revenue reversal exposure
- Operational risk: Company bears full medical-cost risk for approximately 453,600 Medicare Advantage members
- Financial concentration risk: Substantially all receivables come from a small number of payors
Management Discussion & Analysis
- Revenue $1.52B, up 6% YoY from $1.43B, driven by higher PMPM capitation rates and premium yield
- MSER 88.5% vs 104.0% YoY, with medical services expense down 10% to $1.34B
- Best performance: profitable geographies, physician incentive expense $54.9M vs $(18.2)M YoY
- Net income $34.9M vs $(110.2)M; Adjusted EBITDA $63.7M vs $(91.5)M
- Cash and restricted cash $246.4M, marketable securities $65.4M; nine-month operating cash flow $16.3M vs $(85.2)M
AI summary of the AGL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Virtual investor event scheduled for November 17, 2026 at 2:00 PM Eastern
- Presentation webcast available through agilon health’s investor relations website
Item EX-99.1: Item EX-99.1
- Investor presentation outlines agilon’s technology-enabled Total Care Model, emphasizing clinical pathways, physician engagement and quality programs
- Platform scale: ~30 markets, ~2,200 primary care physicians, 500K+ Medicare patients and ~$6B managed medical expense as of December 31, 2025
Item 2.02: Results of Operations and Financial Condition
- Press release covers agilon health’s third-quarter and nine-month results through September 30, 2026
- Investors should review Exhibit 99.1 for reported financial performance and management commentary
Item EX-99.1: Item EX-99.1
- Q3 revenue $1.52B, up 6% YoY despite total platform membership declining 8% to 566,000
- MSER improved to 88.5% from 104.0%, driving net income $35M versus a $110M loss
Item 2.02: Results of Operations and Financial Condition
- Press release announces agilon health financial results for Q2 and first half of fiscal 2026
- Results cover the three and six months ended June 30, 2026
Item EX-99.1: Item EX-99.1
- Q2 revenue rose 7% to $1.495B, while net income reached $18M versus a $104M loss, marking a major profitability inflection
- Medical margin improved to $197M from negative $53M, supported by favorable claims development and medical cost trends
AI summaries of AGL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AGL
Don't miss the next AGL filing
- Alerts as it files. A push when AGL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AGL, by share count.
- Ask anything. An AI agent that reads every AGL filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Gertsch Timothy | F | Aug 16, 2026 | 17 | $96.90 |
| Zamore Denise | F | Aug 1, 2026 | 37 | $91.61 |
| Schwaneke Jeffrey A. | F | Jul 1, 2026 | 2,311 | $111.74 |
| Battaglia Silvana | A | Jun 2, 2026 | 2,133 | - |
| WILLIAMS RONALD A | A | Jun 2, 2026 | 2,133 | - |
| Mansukani Sharad | A | Jun 2, 2026 | 2,133 | - |
| McLoughlin Karen | A | Jun 2, 2026 | 2,133 | - |
| MCKENZIE DIANA | A | Jun 2, 2026 | 2,133 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $4.3B | $6.1B | $5.9B |
| Operating Income | -$232.1M | -$292.1M | -$463.2M |
| Net Income | -$262.6M | -$260.2M | -$391.3M |
| Op. Margin | -5.4% | -4.8% | -7.8% |
| Net Margin | -6.1% | -4.3% | -6.6% |
| Balance Sheet | |||
| Total Assets | $1.7B | $1.7B | $1.3B |
| Equity | - | $471.0M | $126.7M |
| ROE | - | -55.2% | -308.8% |
| Cash Flow | |||
| Operating CF | -$156.2M | -$57.8M | -$105.8M |
| CapEx | $15.8M | $13.3M | $13.2M |
Source: XBRL data in agilon health, inc. (AGL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q4 2025Aggregate AGL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q4 2025 | 25 | $114.2M |
| Q3 2025 | 24 | $177.5M |
| Q2 2025 | 27 | $423.8M |
| Q1 2025 | 25 | $603.9M |
| Q4 2024 | 22 | $124.7M |
- Goldman Sachs Group+13.28M (+196%)
- D.E. Shaw & Co+10.32M (+103%)
- AQR Capital Management+9.51M (+1347%)
- Renaissance Technologies LLC+911.4K (+62%)
- Invesco Ltd+236.0K (+31%)
- FMR LLC (Fidelity)−12.76M (-82%)
- Vanguard Group Inc−5.97M (-25%)
- Morgan Stanley−5.51M (-9%)
- Bank of America Corp−5.13M (-95%)
- JPMorgan Chase & Co−3.72M (-88%)
- Two Sigma Investments+1.11M
- Raymond James Financial+36.0K
- Citizens Financial Group−10.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 123 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AGL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Aug 18, 2026 | - | - | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Jul 22, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 4 | May 27, 2026 | - | - | |
| SC 13G | May 14, 2026 | - | - | |
| SC 13G | May 13, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 8-K | May 6, 2026 | - | Analysis | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 27, 2026 | - | Analysis | - |
| 4 | Apr 16, 2026 | - | - | - |
Related Health Care companies
- DVA · DaVitaServices-Misc Health & Allied Services, NEC
- PGNY · Progyny, Inc.Services-Misc Health & Allied Services, NEC
- VMD · VIEMED HEALTHCARE, INC.Services-Misc Health & Allied Services, NEC
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
AGL SEC filings: frequently asked questions
Which institutions hold AGL stock?
As of December 31, 2025, the largest agilon health, inc. (AGL) holders among the 13F filers tracked by SignalX were Morgan Stanley ($37.1 million), BlackRock ($15.6 million), D.E. Shaw & Co ($14.0 million), Goldman Sachs Group ($13.8 million), Vanguard Group Inc ($12.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AGL's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), agilon health, inc. (AGL) reported revenue of $5.9 billion (down 2.1% from FY2024) and a net loss of $391.3 million. The figures come from the XBRL data in the 10-K.
What did AGL report in its latest 8-K?
agilon health, inc. (AGL) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure). Virtual investor event scheduled for November 17, 2026 at 2:00 PM Eastern.
What are the latest AGL SEC filings?
agilon health, inc. (AGL) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on August 18, 2026.
What is AGL's SEC CIK number?
agilon health, inc. (AGL)'s SEC Central Index Key (CIK) is 1831097. EDGAR lists every AGL filing under that number.
Ask anything about AGL
The research agent reads AGL's filings, financials, insider trades and 13F holders, then answers with sources.